Quick Answer
CG Oncology, Inc. reported Stockholders Equity of $752.60 million for the year ending 2025.
- CG Oncology, Inc. showed an increase of +2.6% in Stockholders Equity from 2024 to 2025.
- This data is from CG Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$86.12 million | Q2 2023: -$97.39 million | Q3 2023: -$107.58 million | Q1 2024: $568.94 million | Q2 2024: $552.36 million | Q3 2024: $536.77 million | Q1 2025: $704.76 million | Q2 2025: $670.36 million | Q3 2025: $687.64 million.
- Over the full 4 years of available data (2022 to 2025), CG Oncology, Inc.'s Stockholders Equity has grown by 1,068.7%.
- Historical annual values: Fiscal year 2025: $752.60 million | Fiscal year 2024: $733.38 million | Fiscal year 2023: -$123.10 million | Fiscal year 2022: -$77.69 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: